NCT01268878

Hematologic Toxicity Observation of the Docetaxel+ Cisplatin+ Fluorouracil (TPF)Medical Protocol

Hematologic Toxicity Observation of the TPF Medical Protocol. Description of the Impact of Febrile Neutropenia in Patients Who Receive the Chemotherapy of the TPF Medical Protocol in Head and Neck Cell Carcinoma

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 130 (actual)
• Sponsor: Groupe Oncologie Radiotherapie Tete et Cou · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The ending of this study is to describe the effect of febrile neutropenia on patients who receive a chemotherapy by docetaxel+cisplatin+fluorouracil(TPF).

Detailed description

In this study we will describe * habits of medical staff in prescription of growth factors or antibiotic prophylaxis * ratio of patients treated by growth factors in primary or secondary prophylaxis * ratio of patients treated in primary prophylaxis who present a febrile neutropenia * ratio of patients who need to be hospitalized and the duration of those hospitalizations. * causes of lateness, of decreasing, and of stop of chemotherapy * antibiotic and growth factors prophylaxis tolerance .

Conditions

• Squamous Cell Head and Neck Carcinoma

Timeline

• Start date: 2010-06-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2010-12-31
• Last updated: 2014-01-03

Locations

18 sites across 1 country: France